Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy
Febuxostat has currently played pivotal role in the treatment of hyperuricemia, but there is little comprehensive information for the determinants of individual difference in efficacy of febuxostat. Therefore, the present study, a retrospective investigation, was carried out to analyze the effects o...
Gespeichert in:
| Veröffentlicht in: | Biological & pharmaceutical bulletin 2017/05/01, Vol.40(5), pp.681-686 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 686 |
|---|---|
| container_issue | 5 |
| container_start_page | 681 |
| container_title | Biological & pharmaceutical bulletin |
| container_volume | 40 |
| creator | Koide, Hiroyoshi Hira, Daiki Tsujimoto, Masayuki Katsube, Yurie Minegaki, Tetsuya Uzu, Takashi Ikeda, Yoshito Morita, Shin-ya Nishiguchi, Kohshi Terada, Tomohiro |
| description | Febuxostat has currently played pivotal role in the treatment of hyperuricemia, but there is little comprehensive information for the determinants of individual difference in efficacy of febuxostat. Therefore, the present study, a retrospective investigation, was carried out to analyze the effects of patient characteristics on the efficacy of febuxostat. A total of 225 patients who were continuously prescribed the same dose of febuxostat for 8–12 weeks from the initial therapy were enrolled in the present study. The data, including patient information and laboratory data, were collected from electronic medical records. Serum urate lowering effects of febuxostat were evaluated by calculating the change in serum urate level at baseline and at 8–12 weeks after starting febuxostat. The multiple regression analysis showed the change in serum urate level was significantly lower in male patients and in those with a lower baseline serum urate level, higher previous dose of allopurinol, lower dose of febuxostat and lower body surface area-unadjusted estimated glomerular filtration rate. Concomitantly administered drugs did not show a significantly influence on the efficacy of febuxostat. In conclusion, it should be noted that the serum urate lowering efficacy of febuxostat may decrease in patients with a higher previous dose of allopurinol, renal impairment or male patients. The basic findings of the present study are believed to contribute to the proper use of febuxostat. |
| doi_str_mv | 10.1248/bpb.b16-00972 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1893971630</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1895830946</sourcerecordid><originalsourceid>FETCH-LOGICAL-c702t-e858460739fe086d58fc2e6c0cc983eb6d973598b4588ab13bc5692eea11a6f23</originalsourceid><addsrcrecordid>eNpdkE1vEzEQhi0EoqFw5IpW4sJly9hefx2r9INKRSABZ8t2ZsNGzjrYuxX99zhJCRKX8WEevfP6IeQthQvKOv3R7_yFp7IFMIo9IwvKO9UKRsVzsgBDdSup0GfkVSkbAFDA-EtyxnQnNBfdgnz-mvFhSHNprlJxa2xS31zGmHZzHsYUm7vSuObblNO4bq5wwrwdRjdOe-wG_fw7lclNzXXfD8GFx9fkRe9iwTdP7zn5cXP9ffmpvf9ye7e8vG9DLTC1qIXuJChuegQtV0L3gaEMEILRHL1cGcWF0b621M5T7oOQhiE6Sp3sGT8nH465u5x-zVgmux1KwBjdiPUvlmrDjaKSQ0Xf_4du0pzH2m5PVQtgOlmp9kiFnErJ2NtdHrYuP1oKdu_ZVs-2erYHz5V_95Q6-y2uTvRfsRW4PQJ1W9XENMZhxH-3Q1F-SDFZBlTV0A5AWGDUgtSHIZkWinNVk5bHpE1VvcbTKZenIUQ8FOvAiv04FTxtw0-XLY78D35Cpd4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1895830946</pqid></control><display><type>article</type><title>Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy</title><source>MEDLINE</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Koide, Hiroyoshi ; Hira, Daiki ; Tsujimoto, Masayuki ; Katsube, Yurie ; Minegaki, Tetsuya ; Uzu, Takashi ; Ikeda, Yoshito ; Morita, Shin-ya ; Nishiguchi, Kohshi ; Terada, Tomohiro</creator><creatorcontrib>Koide, Hiroyoshi ; Hira, Daiki ; Tsujimoto, Masayuki ; Katsube, Yurie ; Minegaki, Tetsuya ; Uzu, Takashi ; Ikeda, Yoshito ; Morita, Shin-ya ; Nishiguchi, Kohshi ; Terada, Tomohiro ; Kyoto Pharmaceutical University ; bDepartment of Pharmacy ; Shiga University of Medical Science Hospital ; Faculty of Pharmaceutical Science ; aDepartment of Clinical Pharmacy ; cDepartment of Medicine</creatorcontrib><description>Febuxostat has currently played pivotal role in the treatment of hyperuricemia, but there is little comprehensive information for the determinants of individual difference in efficacy of febuxostat. Therefore, the present study, a retrospective investigation, was carried out to analyze the effects of patient characteristics on the efficacy of febuxostat. A total of 225 patients who were continuously prescribed the same dose of febuxostat for 8–12 weeks from the initial therapy were enrolled in the present study. The data, including patient information and laboratory data, were collected from electronic medical records. Serum urate lowering effects of febuxostat were evaluated by calculating the change in serum urate level at baseline and at 8–12 weeks after starting febuxostat. The multiple regression analysis showed the change in serum urate level was significantly lower in male patients and in those with a lower baseline serum urate level, higher previous dose of allopurinol, lower dose of febuxostat and lower body surface area-unadjusted estimated glomerular filtration rate. Concomitantly administered drugs did not show a significantly influence on the efficacy of febuxostat. In conclusion, it should be noted that the serum urate lowering efficacy of febuxostat may decrease in patients with a higher previous dose of allopurinol, renal impairment or male patients. The basic findings of the present study are believed to contribute to the proper use of febuxostat.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.b16-00972</identifier><identifier>PMID: 28458354</identifier><language>eng</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Allopurinol ; Allopurinol - administration & dosage ; Allopurinol - therapeutic use ; Electronic medical records ; febuxostat ; Febuxostat - therapeutic use ; gender ; Glomerular Filtration Rate ; Gout - drug therapy ; Gout Suppressants - administration & dosage ; Gout Suppressants - therapeutic use ; Humans ; Hyperuricemia ; Hyperuricemia - drug therapy ; Hyperuricemia - physiopathology ; Kidneys ; Lead poisoning ; Male ; Middle Aged ; Multiple regression analysis ; Patients ; Regression analysis ; Renal function ; renal impairment ; Retrospective Studies ; Treatment Outcome ; urate ; Uric acid ; Uric Acid - blood</subject><ispartof>Biological and Pharmaceutical Bulletin, 2017/05/01, Vol.40(5), pp.681-686</ispartof><rights>2017 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c702t-e858460739fe086d58fc2e6c0cc983eb6d973598b4588ab13bc5692eea11a6f23</citedby><cites>FETCH-LOGICAL-c702t-e858460739fe086d58fc2e6c0cc983eb6d973598b4588ab13bc5692eea11a6f23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28458354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koide, Hiroyoshi</creatorcontrib><creatorcontrib>Hira, Daiki</creatorcontrib><creatorcontrib>Tsujimoto, Masayuki</creatorcontrib><creatorcontrib>Katsube, Yurie</creatorcontrib><creatorcontrib>Minegaki, Tetsuya</creatorcontrib><creatorcontrib>Uzu, Takashi</creatorcontrib><creatorcontrib>Ikeda, Yoshito</creatorcontrib><creatorcontrib>Morita, Shin-ya</creatorcontrib><creatorcontrib>Nishiguchi, Kohshi</creatorcontrib><creatorcontrib>Terada, Tomohiro</creatorcontrib><creatorcontrib>Kyoto Pharmaceutical University</creatorcontrib><creatorcontrib>bDepartment of Pharmacy</creatorcontrib><creatorcontrib>Shiga University of Medical Science Hospital</creatorcontrib><creatorcontrib>Faculty of Pharmaceutical Science</creatorcontrib><creatorcontrib>aDepartment of Clinical Pharmacy</creatorcontrib><creatorcontrib>cDepartment of Medicine</creatorcontrib><title>Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy</title><title>Biological & pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>Febuxostat has currently played pivotal role in the treatment of hyperuricemia, but there is little comprehensive information for the determinants of individual difference in efficacy of febuxostat. Therefore, the present study, a retrospective investigation, was carried out to analyze the effects of patient characteristics on the efficacy of febuxostat. A total of 225 patients who were continuously prescribed the same dose of febuxostat for 8–12 weeks from the initial therapy were enrolled in the present study. The data, including patient information and laboratory data, were collected from electronic medical records. Serum urate lowering effects of febuxostat were evaluated by calculating the change in serum urate level at baseline and at 8–12 weeks after starting febuxostat. The multiple regression analysis showed the change in serum urate level was significantly lower in male patients and in those with a lower baseline serum urate level, higher previous dose of allopurinol, lower dose of febuxostat and lower body surface area-unadjusted estimated glomerular filtration rate. Concomitantly administered drugs did not show a significantly influence on the efficacy of febuxostat. In conclusion, it should be noted that the serum urate lowering efficacy of febuxostat may decrease in patients with a higher previous dose of allopurinol, renal impairment or male patients. The basic findings of the present study are believed to contribute to the proper use of febuxostat.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Allopurinol</subject><subject>Allopurinol - administration & dosage</subject><subject>Allopurinol - therapeutic use</subject><subject>Electronic medical records</subject><subject>febuxostat</subject><subject>Febuxostat - therapeutic use</subject><subject>gender</subject><subject>Glomerular Filtration Rate</subject><subject>Gout - drug therapy</subject><subject>Gout Suppressants - administration & dosage</subject><subject>Gout Suppressants - therapeutic use</subject><subject>Humans</subject><subject>Hyperuricemia</subject><subject>Hyperuricemia - drug therapy</subject><subject>Hyperuricemia - physiopathology</subject><subject>Kidneys</subject><subject>Lead poisoning</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple regression analysis</subject><subject>Patients</subject><subject>Regression analysis</subject><subject>Renal function</subject><subject>renal impairment</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>urate</subject><subject>Uric acid</subject><subject>Uric Acid - blood</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1vEzEQhi0EoqFw5IpW4sJly9hefx2r9INKRSABZ8t2ZsNGzjrYuxX99zhJCRKX8WEevfP6IeQthQvKOv3R7_yFp7IFMIo9IwvKO9UKRsVzsgBDdSup0GfkVSkbAFDA-EtyxnQnNBfdgnz-mvFhSHNprlJxa2xS31zGmHZzHsYUm7vSuObblNO4bq5wwrwdRjdOe-wG_fw7lclNzXXfD8GFx9fkRe9iwTdP7zn5cXP9ffmpvf9ye7e8vG9DLTC1qIXuJChuegQtV0L3gaEMEILRHL1cGcWF0b621M5T7oOQhiE6Sp3sGT8nH465u5x-zVgmux1KwBjdiPUvlmrDjaKSQ0Xf_4du0pzH2m5PVQtgOlmp9kiFnErJ2NtdHrYuP1oKdu_ZVs-2erYHz5V_95Q6-y2uTvRfsRW4PQJ1W9XENMZhxH-3Q1F-SDFZBlTV0A5AWGDUgtSHIZkWinNVk5bHpE1VvcbTKZenIUQ8FOvAiv04FTxtw0-XLY78D35Cpd4</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Koide, Hiroyoshi</creator><creator>Hira, Daiki</creator><creator>Tsujimoto, Masayuki</creator><creator>Katsube, Yurie</creator><creator>Minegaki, Tetsuya</creator><creator>Uzu, Takashi</creator><creator>Ikeda, Yoshito</creator><creator>Morita, Shin-ya</creator><creator>Nishiguchi, Kohshi</creator><creator>Terada, Tomohiro</creator><general>The Pharmaceutical Society of Japan</general><general>Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>2017</creationdate><title>Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy</title><author>Koide, Hiroyoshi ; Hira, Daiki ; Tsujimoto, Masayuki ; Katsube, Yurie ; Minegaki, Tetsuya ; Uzu, Takashi ; Ikeda, Yoshito ; Morita, Shin-ya ; Nishiguchi, Kohshi ; Terada, Tomohiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c702t-e858460739fe086d58fc2e6c0cc983eb6d973598b4588ab13bc5692eea11a6f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Allopurinol</topic><topic>Allopurinol - administration & dosage</topic><topic>Allopurinol - therapeutic use</topic><topic>Electronic medical records</topic><topic>febuxostat</topic><topic>Febuxostat - therapeutic use</topic><topic>gender</topic><topic>Glomerular Filtration Rate</topic><topic>Gout - drug therapy</topic><topic>Gout Suppressants - administration & dosage</topic><topic>Gout Suppressants - therapeutic use</topic><topic>Humans</topic><topic>Hyperuricemia</topic><topic>Hyperuricemia - drug therapy</topic><topic>Hyperuricemia - physiopathology</topic><topic>Kidneys</topic><topic>Lead poisoning</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple regression analysis</topic><topic>Patients</topic><topic>Regression analysis</topic><topic>Renal function</topic><topic>renal impairment</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>urate</topic><topic>Uric acid</topic><topic>Uric Acid - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koide, Hiroyoshi</creatorcontrib><creatorcontrib>Hira, Daiki</creatorcontrib><creatorcontrib>Tsujimoto, Masayuki</creatorcontrib><creatorcontrib>Katsube, Yurie</creatorcontrib><creatorcontrib>Minegaki, Tetsuya</creatorcontrib><creatorcontrib>Uzu, Takashi</creatorcontrib><creatorcontrib>Ikeda, Yoshito</creatorcontrib><creatorcontrib>Morita, Shin-ya</creatorcontrib><creatorcontrib>Nishiguchi, Kohshi</creatorcontrib><creatorcontrib>Terada, Tomohiro</creatorcontrib><creatorcontrib>Kyoto Pharmaceutical University</creatorcontrib><creatorcontrib>bDepartment of Pharmacy</creatorcontrib><creatorcontrib>Shiga University of Medical Science Hospital</creatorcontrib><creatorcontrib>Faculty of Pharmaceutical Science</creatorcontrib><creatorcontrib>aDepartment of Clinical Pharmacy</creatorcontrib><creatorcontrib>cDepartment of Medicine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological & pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koide, Hiroyoshi</au><au>Hira, Daiki</au><au>Tsujimoto, Masayuki</au><au>Katsube, Yurie</au><au>Minegaki, Tetsuya</au><au>Uzu, Takashi</au><au>Ikeda, Yoshito</au><au>Morita, Shin-ya</au><au>Nishiguchi, Kohshi</au><au>Terada, Tomohiro</au><aucorp>Kyoto Pharmaceutical University</aucorp><aucorp>bDepartment of Pharmacy</aucorp><aucorp>Shiga University of Medical Science Hospital</aucorp><aucorp>Faculty of Pharmaceutical Science</aucorp><aucorp>aDepartment of Clinical Pharmacy</aucorp><aucorp>cDepartment of Medicine</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy</atitle><jtitle>Biological & pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2017</date><risdate>2017</risdate><volume>40</volume><issue>5</issue><spage>681</spage><epage>686</epage><pages>681-686</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>Febuxostat has currently played pivotal role in the treatment of hyperuricemia, but there is little comprehensive information for the determinants of individual difference in efficacy of febuxostat. Therefore, the present study, a retrospective investigation, was carried out to analyze the effects of patient characteristics on the efficacy of febuxostat. A total of 225 patients who were continuously prescribed the same dose of febuxostat for 8–12 weeks from the initial therapy were enrolled in the present study. The data, including patient information and laboratory data, were collected from electronic medical records. Serum urate lowering effects of febuxostat were evaluated by calculating the change in serum urate level at baseline and at 8–12 weeks after starting febuxostat. The multiple regression analysis showed the change in serum urate level was significantly lower in male patients and in those with a lower baseline serum urate level, higher previous dose of allopurinol, lower dose of febuxostat and lower body surface area-unadjusted estimated glomerular filtration rate. Concomitantly administered drugs did not show a significantly influence on the efficacy of febuxostat. In conclusion, it should be noted that the serum urate lowering efficacy of febuxostat may decrease in patients with a higher previous dose of allopurinol, renal impairment or male patients. The basic findings of the present study are believed to contribute to the proper use of febuxostat.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>28458354</pmid><doi>10.1248/bpb.b16-00972</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-6158 |
| ispartof | Biological and Pharmaceutical Bulletin, 2017/05/01, Vol.40(5), pp.681-686 |
| issn | 0918-6158 1347-5215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1893971630 |
| source | MEDLINE; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry |
| subjects | Adult Aged Aged, 80 and over Allopurinol Allopurinol - administration & dosage Allopurinol - therapeutic use Electronic medical records febuxostat Febuxostat - therapeutic use gender Glomerular Filtration Rate Gout - drug therapy Gout Suppressants - administration & dosage Gout Suppressants - therapeutic use Humans Hyperuricemia Hyperuricemia - drug therapy Hyperuricemia - physiopathology Kidneys Lead poisoning Male Middle Aged Multiple regression analysis Patients Regression analysis Renal function renal impairment Retrospective Studies Treatment Outcome urate Uric acid Uric Acid - blood |
| title | Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T21%3A46%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Previous%20Dosage%20of%20Allopurinol%20Is%20a%20Strong%20Determinant%20of%20Febuxostat%20Efficacy&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=Koide,%20Hiroyoshi&rft.aucorp=Kyoto%20Pharmaceutical%20University&rft.date=2017&rft.volume=40&rft.issue=5&rft.spage=681&rft.epage=686&rft.pages=681-686&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.b16-00972&rft_dat=%3Cproquest_cross%3E1895830946%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1895830946&rft_id=info:pmid/28458354&rfr_iscdi=true |